Radiation with concomitant superselective intra-arterial cisplatin infusion for maxillary sinus squamous cell carcinoma
| Autor: | Jun Eishima, Takeshi Ebara, Masami Suzuki, Hiroyuki Horikoshi, Takeshi kawakami, Yoshio Tamaki, Ken Ando |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.medical_treatment Urology Antineoplastic Agents 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Phlegmon Sex Factors Mucositis Medicine Humans Infusions Intra-Arterial Radiology Nuclear Medicine and imaging Survival rate Aged Retrospective Studies Cisplatin Univariate analysis Dose-Response Relationship Drug business.industry Squamous Cell Carcinoma of Head and Neck Age Factors Chemoradiotherapy Maxillary Sinus Middle Aged medicine.disease Prognosis Primary tumor Radiation therapy Survival Rate Treatment Outcome 030220 oncology & carcinogenesis Concomitant Female business medicine.drug Follow-Up Studies |
| Zdroj: | Japanese journal of radiology. 37(6) |
| ISSN: | 1867-108X |
| Popis: | To assess the efficacy and prognostic factors after superselective intra-arterial chemoradiation (RADPLAT) for maxillary sinus squamous cell carcinoma (MS-SCC). Prognostic significance of age, gender, T and N factors, gross tumor volume of the primary-site (GTV), total cisplatin dosage, and total cisplatin dosage per GTV (CDDP/GTV) for primary-site recurrence-free survival rate (PRFS) were analyzed. RADPLAT was administered to 27 patients. The median follow-up period was 42.1 months. The 3-year rates of overall survival and PRFS were 59.2% and 53.9%, respectively. In univariate analysis, age, male, and total cisplatin dosage were significant factors for PRFS. In multivariate analysis, lymph node metastasis was significant factors for PRFS, and gender and total cisplatin dosage weakly influenced PRFS. In acute phase, no patient showed ≥ grade 3 hematologic toxicity, and grade 3 mucositis developed in 5 patients. Late toxicities were recognized in 3 patients (grade 2 phlegmon of the face, grade 3 maxillofacial osteonecrosis, and retinopathy). Twelve patients (44%) experienced recurrences. Of them, 8 patients showed recurrence at the primarysite. RADPLAT was effective for MS-SCC, with acceptable toxicity. Total cisplatin dosage is suggested to be important for primary tumor control. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink